Immunic Expects Funding to Last Into Late 2027

Bitget2026/10/19 11:40

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Immunic expects funding to last into late 2027.
Two fully enrolled Phase 3 trials of vidofludimus calcium, totaling 2,221 patients, are expected to deliver top-line results by year-end 2026.
A U.S. regulatory submission is targeted for mid-2027, subject to positive results; potential approval is expected in 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief on October 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Immunic Expects Funding to Last Into Late 2027

You may also like

Crypto prices